 | |
| Clinical data | |
|---|---|
| Trade names | CalBlock,AZUSA,Azovas |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.162.151 |
| Chemical and physical data | |
| Formula | C33H34N4O6 |
| Molar mass | 582.657 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Azelnidipine (INN; marketed under the brand nameCalBlock — カルブロック) is adihydropyridinecalcium channel blocker. Azelnidipine is L and T calcium channel blocker. It is sold inJapan byDaiichi-Sankyo pharmaceuticals, Inc.Drug Controller General Of India (DCGI) has approved the use of azelnipine in India. It is launched under the brand name Azusa (ajanta pharma ltd.)[1] In 2020.
Unlikenicardipine, it has a gradual onset and has a long-lasting antihypertensive effect, with little increase in heart rate.
 | Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byexpanding it. |